NuSepin is under clinical development by Hudson Therapeutics and currently in Phase I for Pneumonia. According to GlobalData, Phase I drugs for Pneumonia have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NuSepin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NuSepin overview

NuSepin is under development for the treatment of Coronavirus disease 2019 (COVID-19) pneumonia, influenza pneumonia and idiopathic pulmonary fibrosis. It is administered through intravenous route. The drug candidate acts by targeting GPCR19.

Hudson Therapeutics overview

Hudson Therapeutics, a subsidiary of Shaperon Inc, is a biotechnology company that focuses on the development of anti-inflammatory and immuno-oncology drugs to address various health conditions. The company is headquartered in Durham, North Carolina, the US.

For a complete picture of NuSepin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.